CONGRESS PROGRAM  Sunday 13 June Thursday   Friday   Saturday   Sunday
	Meet-the-Expert | Simultaneous sessions | Hematology-in-Focus | Plenary session II | Closing Ceremony Please do not forget to pre-register for the Meet-The-Expert sessions in the registration area ! MEET-THE-EXPERT 15 07.30 - 08.15, Salon 2 (Villa Sarasin, ground floor) MONITORING OF CHIMERISM IN TRANSPLANTATION S. McCann (St. James’ s Hospital, Dublin, Ireland) MEET-THE-EXPERT 16 07.30 - 08.15, Salon 17 (Villa Sarasin, 1st floor) MICROARRAYS IN HEMATOLOGY C. Schoch (Laboratory for Leukemia Diagnostics, München, Germany) MEET-THE-EXPERT 17 07.30 - 08.15, Salon 1 (Villa Sarasin, ground floor) GENETIC DIAGNOSIS OF ACUTE LEUKEMIA F. Lo Coco (University Tor Vergata, Rome, Italy) MEET-THE-EXPERT 18 07.30 - 08.15, Salon 13 (Villa Sarasin, 1st floor) RED CELL ANTIGENS AND TRANSFUSION MEDICINE J-P. Cartron (Inserm U76, Paris, France) MEET-THE-EXPERT 19 07.30 - 08.15, Salon 3 (Villa Sarasin, ground floor) TREATMENT OF MDS E. Hellström-Lindberg (Karolinska Institute, Huddinge, Sweden) MEET-THE-EXPERT 20 07.30 - 08.15, Salon 11 (Villa Sarasin, 1st floor) NEONATAL HEMATOLOGY I . Roberts (Imperial College London, London, United Kingdom) MEET-THE-EXPERT 21 07.30 - 08.15, Room Salon 5 (Villa Sarasin, ground floor) CHRONIC MYELOID LEUKEMIA M. Baccarani (University of Bologna, Bologna, Italy)   MEET-THE-EXPERT 22 11.00 - 11.45, Salon 3 (Villa Sarasin, ground floor) NEUTROPENIAS J.E.W. Palmblad (Karolinska Institute, Stockholm, Sweden) MEET-THE-EXPERT 23 11.00 - 11.45, Salon 11 (Villa Sarasin, 1st floor) MOLECULAR CYTOGENETICS H. Döhner (University of Ulm, Ulm, Germany) MEET-THE-EXPERT 24 11.00 - 11.45, Salon 2 (Villa Sarasin, ground floor) CURRENT ROLE OF MORPHOLOGY IN DIAGNOSTICS B. Bain (St.Mary’ s Hospital, London, United Kingdom) MEET-THE-EXPERT 25 11.00 - 11.45, Salon 5 (Villa Sarasin, ground floor) TREATMENT OF DLCL M. Pfreundschuh (University Klinikum des Saarlandes, Homburg, Germany) MEET-THE-EXPERT 26 11.00 - 11.45, Salon 13 (Villa Sarasin, 1st floor) CONGENITAL BLEEDING DISORDERS G. Mariani (Internal Medicine Sanita Pubblica, L’ Aquila, Italy) MEET-THE-EXPERT 27 11.00 - 11.45, Salon 17 (Villa Sarasin, 1st floor) MANAGEMENT OF SICKLE CELL DISEASE P. Darbyshire (Birmingham Children’ s Hospital, Birmingham, United Kingdom) MEET-THE-EXPERT 28 11.00 - 11.45, Salon 1 (Villa Sarasin, ground floor) DIFFERENTIAL DIAGNOSIS OF CHRONIC LYMPHOPROLIFERATIVE DISORDERS G.A. Pangalis (University of Athens, Athens, Greece) Top SIMULTANEOUS SESSION 08:30 - 09:45, Room A (Geneva Palexpo) MOLECULAR CYTOGENETICS IN MULTIPLE MYELOMA & CHRONIC LYMPHOCYTIC LEUKEMIA Chairs:  F. Caligaris Cappio (San Raffaele del Monte Tabor Center, Milan, Italy) H. Döhner (University of Ulm, Ulm, Germany)   08:30 - 08:45 582 PATHOGENETIC RELEVANCE AND PROGNOSTIC VALUE OF GENOMIC IMBALANCES IN CLONAL PLASMA CELL DISORDERS P. Liebisch, C. Wendl, D. Scheck, A. Wellmann, S. Erné, K. Tschajka, M. Kirschenlohr, C. Straka, H. Goldschmidt, H. Einsele, A. Benner, H. Döhner (University Hospital of Ulm, Ulm, Germany)   08:45 - 09:00 583 CK2 SERINE-THREONINE KINASE CONTROLS MULTIPLE MYELOMA CELLS SURVIVAL AND PROLIFERATION AND ITS SELECTIVE BLOCK LEADS TO GROWTH ARREST, APOPTOSIS AND ALTERED NFKB SIGNALING F. Piazza, M. Ruzzene, F. Barbon, G. Di Maira, L. Trentin, F. Adami, A. Cabrelle, L.A. Pinna, G. Semenzato (Venetian Institute of Molecular Medicine, Padova, Italy)   09:00 - 09:15 584 ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION REVEALS A DNA LOSS AT 14Q32.33 AS A NEW PROGNOSTIC MARKER IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) D. Drandi (Osp. S.Giovanni Battista, Turin, Italy)   09:15 - 09:30 585 FREQUENCY AND PROGNOSTIC RELEVANCE OF T(4;14) IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA (MM) PATIENTS RECEIVING EITHER SINGLE OR DOUBLE AUTOTRANSPLANTS C. Terragna, M. Renzulli, M. Cavo, S. Soverini, C. Cellini, N. Testoni, A. De Vivo, M. Amabile, B. Giannini, E. Ottaviani, T. Grafone, E. Zamagni, P. Tosi, D. Cangini, P. Tacchetti, S. Tura, M. Baccarani, G. Martinelli (“L. and A. Seragnoli”, Bologna, Italy)   09:30 - 09:45 586 ASSOCIATION BETWEEN IMMUNOPHENOTYPE AND FLUORESCENT IN-SITU YBRIDIZATION (FISH) ANALYSIS IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA A. Marin Niebla, E. Rios Herranz, J. Rodriguez Fernandez, A. Herrera, R. Parody Ruiz-Berdejo (Hospital Virgen del Rocio, Sevilla, Spain)   SIMULTANEOUS SESSION 08:30 - 09:45, Le Mont-Blanc / Le Cervin (Geneva Palexpo) AML: THERAPY Chairs:  M. Sanz (Hospital Universitario La Fe, Valencia, Spain) A.K. Burnett (University Hospital Wales, Cardiff, United Kingdom)   08:30 - 08:45 587 INTENSIVE CONSOLIDATION VERSUS ORAL MAINTENANCE THERAPY IN PATIENTS >60 YEARS WITH ACUTE MYELOID LEUKEMIA: RESULTS OF THE RANDOMIZED AML HD98B TRIAL OF THE AMLSG ULM F. Schlenk, S. Fröhling, F. Hartmann, J.TH. Fischer, A . Glasmacher, F. del Valle, W. Grimminger, K. Götze, C. Waterhouse, H. Pralle, E. Koller, H. Salwender, F. Griesinger, K. Döhner, H. Döhner (University Hospital of Ulm, Ulm, Germany)   08:45 - 09:00 588 RANDOMISED COMPARISON OF FLA VERSUS ADE, WITH OR WITHOUT G-CSF AND WITH OR WITHOUT ATRA, FOR HIGH-RISK AML: RESULTS OF THE MRC AML-HR TRIAL. D.W Milligan, K. Wheatley, J.I.O. Craig, T.J. Littlewood, A.K. Burnett (Birmingham Heartlands Hospital, Birmingham, United Kingdom)   09:00 - 09:15 589 A COMPARISON OF LOW DOSE ARA-C AND HYDROXYUREA WITH AND WITHOUT ALL RETINOIC ACID IN ACUTE MYELOID LEUKAEMIA PATIENTS NOT CONSIDERED FIT FOR CHEMOTHERAPY: RESULTS FROM NCRI LRF AML14 TRIAL A.K. Burnett, D. Milligan, A.G. Prentice, A.H. Goldstone, M. McMullin, K. Wheatley (University of Wales College of Medicine, Cardiff, United Kingdom)   09:15 - 09:30 590 VACCINATION WITH WT1 INDUCES HIGH FREQUENCY MEMORY AND EFFECTOR T CELLS IN PERIPHERAL BLOOD AND BONE MARROW ASSOCIATED WITH COMPLETE REMISSION OF RECURRENT AML A. Letsch, C. Scheibenbogen, E. Thiel, A.M. Asemissen, U. Keilholz (Charite, Campus Benjamin Franklin, Berlin, Germany)   09:30 - 09:45 591 ROLE OF AUTOTRANSPLANTATION AS LATE CONSOLIDATION THERAPY IN ADULTS WITH STANDARD RISK ACUTE MYELOID LEUKEMIA AGED </= 60 YEARS: RESULTS OF A PROSPECTIVE RANDOMIZED MULTICENTER TRIAL A. Ganser, J. Krauter, D. Hoelzer, O.G. Ottmann, H. Martin, M. Lübbert, J. Finke, W. Heit, W. Fiedler, D. Hossfeld, L. Kanz, G. Schlimok, H. Kirchner, A. Raghavachar, W. Brugger, G. Heil (Hannover Medical School, Hannover, Germany) SIMULTANEOUS SESSION 08:30 - 09:45, Room C (Geneva Palexpo) LYMPHOMA & OTHER LPD: TREATMENT Chairs:  M. Björkholm (Karolinska Institute, Stockhom, Sweden) E. Matutes (Royal Marsden Hospital, London, United Kingdom)   08:30 - 08:42 592 MONOTHERAPY WITH THE ANTI-CD20 ANTIBODY RITUXIMAB (RITUX) IN PATIENTS WITH POST-TRANSPLANT LYMPHO-PROLIFERATIVE DISEASE (PTLD) RESULTS OF A MULTICENTRE PHASE II STUDY H.K. Oertel, K. Zeidler, P. Reinke, S. Jonas, E. Verschuuren, U. Jäger, M. Jerkeman, J. Niedermeyer, M. Hallek, M. Hummel, I. Anagnostopoulos, B. Dörken, H. Riess (Humboldt Uni / Charite - Campus Virchow, Berlin, Germany)   08:42 - 08:54 593 THE MINT TRIAL (CHOP-LIKE REGIMENS WITH OR WITHOUT RITUXIMAB FOR YOUNG LOW-RISK PATIENTS WITH DIFFUSE LARGE B-CELL NON-HODKIN’ S LYMPHOMA [DLBCL]): EARLY STOPPING AFTER FIRST INTERIM ANALYSIS M. Pfreundschuh (Saarland University Medical School, Homburg, Germany)   08:54 - 09:06 594 SEQUENTIAL TREATMENT WITH FLUDARABINE AND SUBCUTANEOUS ALEMTUZUMAB IS ABLE TO PURGE RESIDUAL DISEASE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA M.M. Montillo, A. Tedeschi, V. Rossi, A.M. Cafro, M. Montagna, L. Intropido, R. Cairoli, M. Gambacorta, S. Veronese, B. Scarpati, M. Regazzi, E. Morra (Niguarda Ca’ Granda Hospital, Milano, Italy)   09:06 - 09:18 595 A PHASE II STUDY OF PROTEASOME INHIBITOR BORTEZOMIB IN RELAPSED OR REFRACTORY INDOLENT OR AGGRESSIVE B-CELL NON-HODGKIN’ S LYMPHOMA A.G. Goy, A. Younes, P. McLaughlin, B. Pro, J.E. Romaguera, F. Hagemeister, L. Fayad, N.H. Dang, F. Samaniego, M. Wang, T.L. Smith, K. Broglio, B. Samuels, F. Gilles, A.H. Sarris, S. Hart, E. Trehu, D. Schenkein, F. Cabanillas, A. Rodriguez (MD Anderson Cancer Center, Houston, USA)   09:18 - 09:30 596 P-VABEC-CIP REGIMEN IMPROVES SURVIVAL IN ELDERLY PATIENTS WITH DIFFUSE LARGE CELLS LYMPHOMAS. FINAL RESULTS OF AN ITALIAN MULTICENTER RANDOMIZED STUDY M.M. Martelli, M. Petrini, F. Caracciolo, A. Perrotti, E. Iannitto, A. Andriani, C. Minotti, E. Finolezzi, M. Giovannini, M. Montanaro, F. Mandelli, R. Foà (University “La Sapienza”, Rome, Italy)   09:30 - 09:42 597 ANGIOGENESIS IN HODGKIN’ S LYMPHOMA: A MORPHOMETRIC APPROACH IN 286 PATIENTS WITH PROGNOSTIC IMPLICATIONS P. Korkolopoulou, I. Thymara, N. Kavantzas, T.P. Vassilakopoulos, M.K. Angelopoulou, S.I. Kokoris, E.M. Dimitriadou, M.P. Siakantaris, M.N. Dimopoulou, K. Anargyrou, P. Panayiotidis, A. Androulakis, I.A. Doussis-Anagnostopoulou, E. Patsouris, G.A. Pangalis (University of Athens, Athens, Greece)   09:42 - 09:45   DISCUSSION   SIMULTANEOUS SESSION 08:30 - 09:45, Le Jura (Geneva Palexpo) ANEMIA Chairs:  M. Solenthaler (Inselpital, Bern, Switzerland) A. Tichelli (Institute Hematology, Basel, Switzerland)   08:30 - 08:42 598 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS DISPLAY HIGH FREQUENCY OF PERIPHERAL BLOOD NKT CELLS EXPRESSING ACTIVATING ISOFORMS OF INHIBITING SUPERFAMILY RECEPTORS (IRS). A.P. Poggi, S.M. Negrini, M.R. Zocchi, A.M. Massaro, L. Gargiulo, R. Notaro, L. Luzzatto (National Institute for Cancer Research, Genoa, Italy)   08:42 - 08:54 599 RITUXIMAB IN CHRONIC COLD AGGLUTININ DISEASE: A PROSPECTIVE STUDY OF 20 PATIENTS S. Schoellkopf, L. Kjeldsen, O.W. Bjerrum, H.T. Mourits-Andersen, J.L. Nielsen, B.E. Christensen, B.A. Jensen, B.B. Pedersen, H. Birgens (Herlev University Hospital, Herlev, Denmark)   08:54 - 09:06 600 ACTIVATED T-LYMPHOCYTES WITH MYELOSUPPRESSIVE PROPERTIES IN THE PERIPHERAL BLOOD (PB) AND BONE MARROW (BM) MICROENVIRONMENT OF PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA (CIN) H.A. Papadaki, K. Stamatopoulos, A. Damianaki, C. Gemetzi, H. Koutala, C. Pontikoglou, C. Kastrinaki, K. Pyrovolaki, G.D. Eliopoulos (University of Crete School of Medicine, Heraklion, Greece)   09:06 - 09:18 601 IMPAIRED ERYTHROPOIESIS IN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA (CIN) C. Pontikoglou, A. Damianaki, C. Gemetzi, H. Koutala, K. Pyrovolaki, G.D. Eliopoulos, H.A. Papadaki (University of Crete School of Medicine, Heraklion, Greece)   09:18 - 09:30 602 PRODAPTIN-CD59, A MEMBRANE-TARGETED RECOMBINANT CD59, COATS PNH RED CELLS IN VITRO AND MURINE RED CELLS IN VIVO PROTECTING BOTH FROM HUMAN COMPLEMENT MEDIATED LYSIS A. Sah, S.H. Ridley, S.J. Richards, M.J. Cullen, R.G. Oldroyd, J. White, D. Esser, P. Hillmen (Leeds General Infirmary, Leeds, United Kingdom)   09:30 - 09:42 603 INDEPENDENT RISK FACTORS FOR ANEMIA IN PATIENTS WITH LYMPHOMA/MYELOMA ARE DEFINED BY LOGISTIC REGRESSION MODELING: RESULTS FROM THE EUROPEAN CANCER ANAEMIA SURVEY (ECAS) G. Birgegard, H. Ludwig, J. Nortier, D. Schrijvers, P. Gascón (University Hospital, Uppsala, Sweden)   09:42 - 09:45   DISCUSSION SIMULTANEOUS SESSION 08:30 - 09:45, Room D (Geneva Palexpo) MOLECULAR BIOLOGY Chairs:  A.W. Langerak (Erasmus Medical Center, Rotterdam, The Netherlands) J. Schwaller (Geneva University Hospital, Geneva, Switzerland)   08:30 - 08:45 604 INDUCTION OF GENOMIC INSTABILITY BY V(D)J-MEDIATED TRANSPOSITION OF SIGNAL JOINTS K. Vanura, R. Marculescu, T. Le, U. Jaeger, B. Nadel (Medical University Vienna, Vienna, Austria)   08:45 - 09:00 605 CODING JOINT FORMATION IS INHIBITED IN V(D)J-MEDIATED TRANSLOCATIONS FROM HEALTHY INDIVIDUALS T. Le, B. Montpellier, R. Marculescu, K. Vanura, E. Vachez, P. Ferrier, U. Jaeger, B. Nadel (Medical University of Vienna, Vienna, Austria)   09:00 - 09:15 606 TELOMERE LENGTH CORRELATES WITH HISTOPATOGENESIS ACCORDING TO THE GERMINAL CENTER IN MATURE B-CELL LYMPHOPROLYPHERATIVE DISORDERS M.M.L. Ladetto, I. Ricca, M. Compagno, A. Rocci, M. Pagano, P. Francia di Celle, M. Astolfi, D. Drandi, F. de Marco, F. De Marco, S. Vallet, L. Santo, C. Marinone, M. Boccadoro, C. Tarella (Università di Torino, Torino, Italy)   09:15 - 09:30 607 THE SMALL OLIGOMERIZATION DOMAIN OF GEPHYRIN CONVERTS MLL TO AN ONCOGENE M. Eguchi-Ishimae, M. Eguchi, M. Greaves (Leukaemia Research Fund Centre, London, United Kingdom)   09:30 - 09:45 608 THE PEPTIDYL PROLYL CIS/TRANS ISOMERASE PIN1 INTERACTS WITH ETV6 AND CONVERTS ETV6 FROM A TRANSCRIPTIONAL REPRESSOR TO A TRANSCRIPTIONAL ACTIVATOR C.D. Zhang, J. Putnik, S.K. Bohlander (Klinikum Grosshadern, Munich, Germany)   SIMULTANEOUS SESSION 11:00 - 12:15, Room A (Geneva Palexpo) STEM CELL TRANSPLANTATION II Chairs:  R. Hehlmann (III Medizinische Universitätsklinik, Mannheim, Germany) J-P. Vernant (Hôpital Pitie Salpetriere, Paris, France)   11:00 - 11:15 609 REDUCED-INTENSITY ALLOGRAFTING FOR CHRONIC MYELOID LEUKAEMIA IN THE FIRST CHRONIC PHASE M. Doubek, M. Krejci, A. Vitek, Y. Brychtova, J. Mayer (University Hospital Brno, Brno, Czech Republic)   11:15 - 11:30 610 CLINICAL OUTCOME AND PROGNOSTIC FACTORS OF HIGH-DOSE CHEMOTHERAPY (HDT) AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PERIPHERAL T-CELL LYMPHOMA (PTCL) S. Cortelazzo, A. Rossi, P. Viero, T. Motta, A. Rambaldi, T. Barbui (Ospedali Riuniti Bergamo, Bergamo, Italy)   11:30 - 11:45 611 EFFECT OF AGE AND FAILED AUTOLOGOUS TRANSPLANT ON TREATMENT-RELATED MORTALITY AND GVHD IN 110 PATIENTS TREATED WITH REDUCE-INTENSITY CONDITIONING AND ALLOGRAFT FOR ADVANCED HEMATOLOGICAL MALIGNANCIES P. Corradini, F. Zallio, J. Mariotti, M. Bregni, F. Ciceri, A. Bacigalupo, A. Dodero, M. Lucesole, F. Patriarca, A. Rambaldi, R. Scimè, I. Majolino, G. Bandini, A.M. Gianni, C. Tarella, A. Olivieri (Istituto Nazionale Tumori di Milano, Milano, Italy)   11:45 - 12:00 612 IMATINIB INDUCES SUSTAINED MOLECULAR REMISSIONS IN POST-TRANSPLANT MOLECULAR RELAPSE OF PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) B. Wassmann, H. Pfeifer, P. Brück, M. Stadler, M. Bornhäuser, S.A. Klein, N. Basara, R. Schwerdtfeger, M. Stelljes, D. Bunjes, J. Perz, G. Ledderose, A. Binckebanck, H. Gschaidmeier, D. Hoelzer, O.G. Ottmann (Johann Wolfgang Goethe University, rankfurt, Germany)   12:00 - 12:15 613 BUSULFAN SYSTEMIC EXPOSURE IN ADULTS OBTAINED AFTER ORAL VS. INTRAVENOUS ADMINISTRATION: DEMONSTRATION OF DOSING EQUIVALENCE BASED ON COMPARISON OF SYSTEMIC EXPOSURE (AUC) VALUES B. Andersson, C. Puozzo, L. Nguyen, S. Lennon, A. Krishnan, H. Fung, M. O’ Donnell, R. Spielberger, R. Bhatia, N. Kogut, K. Chang, A. Stein, D. Smith, S. Forman (MD Anderson, Houston, USA) SIMULTANEOUS SESSION 11:00 - 12:15, Le Mont-Blanc / Le Cervin (Geneva Palexpo) ACUTE LYMPHOBLASTIC LEUKEMIA Chairs:  J.M. Ribera (Catala Dóncologia Institute, Badalona, Spain) N. Gökbuget (University of Frankfurt, Frankfurt, Germany)   11:00 - 11:15 614 INDIVIDUAL OUTCOME OF ADULT PATIENTS WITH COMMONLY DEFINED STANDARD RISK B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA CAN BE PREDICTED BY GENE EXPRESSION PROFILING. W-K. Hofmann, M. Komor, G. Huetter, S. Schwartz, N. Gökbuget, S. de Vos, O.G. Ottmann, E. Thiel, D. Hoelzer (University Hospital, Frankfurt/Main, Germany)   11:15 - 11:30 615 EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) ON THE OUTCOME OF BURKITT’ S LYMPHOMA AND LEUKEMIA IN ADULT HIV INFECTED PATIENTS TREATED IN THE PETHEMA ALL3/97 PROTOCOL A.O. Oriol, J.M. Ribera, J. Esteve, S. Brunet, M.A. Sanz, R. Garcia-Boyero, M.D. Peñarrubia, E. Abella, J. Besalduch, M. Sanchez-Delgado, P. Fernández-Abellán, S. Del Potro, D. Borrego, J.J. Ortega, E. Feliu (Hospital Univ Germans Trias i Pujol, Badalona, Spain)   11:30 - 11:45 616 MONITORING OF MRD LEVELS UNRAVELS A GREAT HETEROGENEITY WITHIN T(12;21)-POSITIVE CHILDHOOD ALL PATIENTS G. Cazzaniga, C. Palmi, D. Silvestri, M. Spinelli, L. Corral, G. Germano, M. Manenti, L. Del Giudice, T. Villa, S. Songia, E. D’ Aniello, G. Masera, M.G. Valsecchi, G. Basso, A. Biondi (Centro Ricerca Tettamanti, Monza, Italy)   11:45 - 12:00 617 THE BCR/ABL ISOFORMS AFFECT THE PRESENTING FEATURES AND TREATEMENT OUTCOME OF PATIENTS WITH PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SEVEN-YEAR UPDATE OF THE GIMEMA 0496 TRIAL.. C. Cimino, L. Elia, E. Finolezzi, A. Capparucci, M. Vignetti, M. Mancini, C. Mecucci, A. Cuneo, F. Pane, G. Saglio, A. Recchia, E. Gallo, E. Morra, R. Foà, F. Mandelli (University “La Sapienza”, Rome, Italy)   12:00 - 12:15 618 INTEGRATED ANALYSIS OF GENE EXPRESSION AND SINGLE NUCLEOTIDE POLYMORPHISMS: IDENTIFICATION OF A DISTINCTIVE GENE EXPRESSION SIGNATURE ASSOCIATED WITH LOH ON CHROMOSOME 9P IN ADULT ALL S. Chiaretti, X. LI, R. Gentleman, A. Vitale, M. Mancini, C. Mecucci, R. Foà, J. Ritz (Dana Farber Cancer Institute, Boston, USA)   SIMULTANEOUS SESSION 11:00 - 12:15, Room C (Geneva Palexpo) AML: MOLECULAR BIOLOGY Chairs:  T. Haferlach (Medical University Munich, Munich, Germany) T. Pabst (Institute of Medical Oncology, Bern, Switzerland)   11:00 - 11:12 619 ACUTE MYELOID LEUKEMIA WITH DELETION 9Q IS ASSOCIATED WITH CEBPA LOSS-OF-FUNCTION MUTATIONS S. Fröhling, R. F. Schlenk, J. Krauter, C. Thiede, G. Ehninger, D. Haase, L. Harder, S. Kreitmeier, C. Scholl, M.A. Caligiuri, C.D. Bloomfield, H. Döhner, K. Döhner (University Hospital of Ulm, Ulm, Germany)   11:12 - 11:24 620 ONCOGENIC ROLE OF THE P110 -DELTA-ISOFORM OF PI3K IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA V. Bardet, P. Sujobert, P. Cornillet, O. Muller, N. Ifrah, C. Berthou, G. Guillerm, B. Witz, L. Legros, T. Lamy, D. Guyotat, B. Lioure, F. Dreyfus, P. Mayeux, C. Lacombe, D. Bouscary (INSERM U567 Institut Cochin, Paris, France)   11:24 - 11:36 621 GENE EXPRESSION PROFILING BASED IDENTIFICATION OF NEW SUBCLASSES IN ADULT ACUTE MYELOID LEUKEMIA L. Bullinger, K. Döhner, E. Bair, S. Fröhling, R.F. Schlenk, R. Tibshirani, H. Döhner, J.R. Pollack (University of Ulm, Ulm, Germany)   11:36 - 11:48 622 INSERTIONS GENERATING THE 5’ AML1/3’ ETO GENE IN ACUTE MYELOID LEUKEMIA CASES SHOW VARIABLE BREAKPOINTS G. Specchia, F. Albano, L. Anelli, A. Zagaria, M. Mancini, R. La Starza, A. Liso, L. Sebastio, G. Saglio, V. Liso, M. Rocchi (Hematology-University of Foggia, Foggia, Italy)   11:48 - 12:00 623 CYTOTOXIC POTENTIAL AND ANTI-LEUKEMIC EFFECT OF NATURAL KILLER CELLS FROM AML PATIENTS AGAINST AUTOLOGOUS LEUKEMIC BLASTS IN VITRO AND IN VIVO AFTER ADOPTIVE TRANSFER TO NOD/SCID MICE S.U. Siegler, C.P. Kalberer, P. Nowbakht, S. Meyer-Monard, A. Tichelli, A. Wodnar-Filipowicz (Kantonsspital Basel, Basel, Switzerland)   12:00 - 12:12 624 ACUTE MYELOID LEUKEMIA: GROSS GENETIC INSTABILITY IS ASSOCIATED WITH CRITICAL TELOMERE SHORTENING AND REACTIVATION OF TELOMERASE J.M.J.M. Zijlmans, S.J.J. Swiggers, M.A. Kuijpers, M.J. de Cort, H.B. Beverloo (Erasmus University Medical Center, Rotterdam, The Netherlands)   12:12 - 12:15   DISCUSSION SIMULTANEOUS SESSION 11:00 - 12:15, Le Jura (Geneva Palexpo) TRANSFUSION MEDICINE & IMMUNOHEMATOLOGY Chairs:  W. Flegel (University Hospital Ulm, Ulm, Germany) F. Noizat-Pirenne (EFS Hôpital Henri mondor, Créteil, France)   11:00 - 11:15 625 EARLY DETECTION AND RAPID ISOLATION OF ACUTE LYMPHOBLASTIC LEUKEMIA-REACTIVE DONOR T CELLS FOR ADOPTIVE TRANSFER USING THE INTERFERON-GAMMA SECRETION ASSAY I. Jedema, E. Steeneveld, B. Jharap, B.A. Nijmeijer, F.M. Kloosterboer, R. Willemze, J.H.F. Falkenburg (Leiden University Medical Center, Leiden, The Netherlands)   11:15 - 11:30 626 REPRODUCIBLE, CLINICAL GRADE GENERATION OF HLA-MATCHED DONOR DERIVED CYTOTOXIC T CELLS AGAINST AML AND ALL BLASTS A.M. Barbui, G. Borleri, M. Micò, A. Salvi, M. Introna, A. Rambaldi (Ospedali Riuniti di Bergamo, Bergamo, Italy)   11:30 - 11:45 627 IMMATURE PLATELET FRACTION MEASUREMENT: A FUTURE GUIDE TO PLATELET TRANSFUSION REQUIREMENT AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION D.P. Hart, C. Briggs, S. Kunka, S. Oguni, S.J. Machin (University College London Hospital, London, United Kingdom)   11:45 - 12:00 628 INTERCEPT PLATELETS EXHIBIT IMMUNOLOGIC REFRACTORINESS COMPARABLE TO CONVENTIONAL PLATELETS R.G. Strauss, S. Slichter, I. Lopez-Plaza, L.T. Goodnough, J. McCullough, J-S. Lin, M.G. Conlan (University of Iowa, Iowa City, USA)   12:00 - 12:15 630 PEGYLATION OF HUMAN RED BLOOD CELLS INDUCES SUSCEPTIBILITY TO COMPLEMENT MEDIATED LYSIS A.S. Stassinopoulos, S. Mathur, X.M. Zhou, S. Bowers, G. Castro (Cerus Coproration, Concord, USA)   SIMULTANEOUS SESSION 11:00 - 12:15, Room D (Geneva Palexpo) STEM CELLS & IMMUNOTHERAPY Chairs:  M. Duchosal (CHUV, Lausanne, Switzerland) P. Tiberghien (Etablissement Français du Sang, Besançon, France)   11:00 - 11:15 631 MOBILIZED PERIPHERAL BLOOD AND CORD BLOOD: TWO OTHER REAL SOURCES OF MESENCHYMAL STEM CELLS T. Tondreau, A. Delforge, M. Dejeneffe, R. Leroy, M. Massy, C. Mortier, D. Bron, L. Lagneaux (Jules Bordet Institute, Brussels, Belgium)   11:15 - 11:30 632 IDENTIFICATION OF RPS4Y AS A HLA-B*5201-RESTRICTED H-Y ANTIGEN OVEREXPRESSED BY PROLIFERATING B AND T CELLS R. Ivanov, S. Hol, T. Aarts, A. Hagenbeek, E. Petersen, S. Ebeling (University Medical Center Utrecht, Utrecht, The Netherlands)   11:30 - 11:45 633 EXPANSION OF HUMAN UMBILICAL CORD BLOOD-DERIVED CD34+ STEM/PROGENITOR CELLS TO TREAT MYOCARDIAL INFARCTION A. Nagler, F. Grynspan, T. Peled, E. Landau, J. Mandel, E. Guetta, R. Holbova, M.S. Feinberg, J. Leor (Chaim Sheba Medical Center, Tel Hashomer, Israel)   11:45 - 12:00 634 PGP (MDR1)-DEPENDENT RESISTANCE OF MALIGNANT CELLS TOWARDS NATURAL KILLER (NK) CELLS IS REVERSED BY IL-2 AND KT-5720: IMPLICATIONS ON GRAFT-VERSUS-TUMOR (GVT) EFFECTS IN ADOPTIVE IMMUNOTHERAPY H.G Galski, I. Bar, O. Ostrovsky, A. Nagler (Chaim Sheba Medical Center, Tel Hashomer, Israel)   12:00 - 12:15 635 A NEW ROAD TO T CELL DIVERSIFICATION C. Joao, B.M. Ogle, J.L. Platt, M. Cascalho (Transplantation Biology, Rochester, MN, USA) Top HEMATOLOGY-IN-FOCUS SESSION 10:00 - 10:45, Room A (Geneva Palexpo) VENOUS THROMBOEMBOLISM Chair:  H. Bounameaux (University Hospital Geneva, Geneva, Switzerland) EPIDEMIOLOGY C. Doggen (Leiden University Medical Center, Leiden, The Netherlands) THE VALUE OF D-DIMERS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM H. Bounameaux (University Hospital Geneva, Geneva, Switzerland) HEMATOLOGY-IN-FOCUS SESSION 10:00 - 10:45, Room C (Geneva Palexpo) MONOCLONAL GAMMOPATHIES Chair:  H. Ludwig (Wilhelminenspital, Vienna, Austria) THE EVOLVING VERSUS NON-EVOLVING NATURE OF ASYMPTOMATIC MONOCLONAL GAMMOPATHIES (MGUS AND SMM) J. Bladé (Hospital Clinic Barcelona, Barcelona, Spain) AMYLOIDOSIS G. Merlini (Biotechnology Research Laboratories, Pavia, Italy) HEMATOLOGY-IN-FOCUS SESSION 10:00 - 10:45, Room Le Mont-Blanc / Le Cervin (Geneva Palexpo) IMPACT OF NEW MOLECULAR ABNORMALITIES IN CLL Chair:  T.J. Hamblin (University of Southampton, Bournemouth, United Kingdom) ROLE OF ZAP70 IN CLL E. Montserrat (Hospital Clinic Barcelona, Barcelona, Spain) GENE REARRANGEMENT IN CLL G. Dighiero (Institute Pasteur, Paris, France)   HEMATOLOGY-IN-FOCUS SESSION 10:00 - 10:45, Room Le Jura (Geneva Palexpo) CLUSTERING & FAMILIAL LEUKEMIA Chair:  L. Degos (Hospital Saint Louis, Paris, France) EPIDEMIOLOGY G. Morgan (Royal Marsden Hospital, Sutton, United Kingdom) FAMILIAL CLL: THE SEARCH FOR PREDISPOSITION GENES D. Catovsky (Institute of Cancer Research, London, United Kingdom) HEMATOLOGY-IN-FOCUS SESSION 10:00 - 10:45, Room D (Geneva Palexpo) MOLECULAR CONNECTIONS BETWEEN ERYTHROPOEISIS AND IRON METABOLISM Chair:  Ph. Beris (University Hospital Geneva, Geneva, Switzerland) REGULATION OF IRON HOMEOSTASIS BY HEPCIDINE C. Beaumont (Medical Faculty Xavier Bichat, Paris, France) REGULATION OF ERYTHROPOIESIS BY HYPOXIA C. Pugh (University of Oxford, Oxford, United Kingdom) HEMATOLOGY-IN-FOCUS SESSION 10:00 - 10:45, Room H (Geneva Palexpo) MICROARRAYS IN LYMPHOMA Chair:  E. Zucca (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) A DIAGNOSTIC TOOL C. Thieblemont (Centre hospitralier Lyon-Sud, Pierre-Benité, France) A PROGNOSTIC INDICATOR A. Rosenwald (University of Wuerzburg, Wuerzburg, Germany) Top SIMULTANEOUS SESSION 11:00 - 12:15, Room H (Geneva Palexpo) CHRONIC LYMPHOCYTIC LEUKEMIA: BIOLOGY ZAP Chairs:  A. Rambaldi (Ospedali Riuniti, Bergamo, Italy) F. Bosch (Hospital Clinic Barcelona, Barcelona, Spain)   11:00 - 11:15 636 ZAP-70 PROTEIN TYROSINE KINASE IS AN INDEPENDENT MARKER OF DISEASE PROGRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA G. Del Poeta, M.I. Del Principe, L. Maurillo, M. Irno Consalvo, A. Venditti, F. Buccisano, R. Marini, R. Bomben, M. Degan, M. Dal Bo, M.C. Cox, P. Panetta, D. Piccioni, G. Suppo, M. Cecconi, V. Gattei, S. Amadori (S.Eugenio Hospital, Univ. Tor Vergata, Roma, Italy)   11:15 - 11:30 637 CXCL12 INDUCES ACTIN POLYMERISATION AND SUSTAINED ERK ACTIVATION IN B-CLL CELLS EXPRESSING ZAP-70 S.J. Richardson, J.A. Copplestone, A.G. Prentice (Derriford Hospital, Plymouth, United Kingdom)   11:30 - 11:45 638 ZAP-70 PROTEIN EXPRESSION IS NEGATIVE, AND THE GENE PROMOTER REGION IS METHYLATED, IN MOST CASES OF MCL AND SLVL, AND DOES NOT CORRELATE WITH IGVH GENE MUTATIONAL STATUS J.A. Orchard, Z. Davis, A. Parker, R. Ibbotson, C. Feeley, D.G. Oscier (Royal Bournemouth Hospital, Bournemouth, United Kingdom)   11:45 - 12:00 639 ZAP-70 EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKAEMIA: CORRELATION WITH CLINICAL AND BIOLOGICAL FEATURES I. Del Giudice, E. Matutes, A. Morilla, R. Morilla, A. Burford, S. Maravelaki, N. Osuji, K. Owusu-Ankomah, V. Brito-Babapulle, D. Catovsky (Royal Marsden Hospital-ICR, London, United Kingdom)   12:00 - 12:15   DISCUSSION   PLENARY SESSION 2 12:30 - 14:00, Plenary room (A+B+C, Geneva Palexpo) PRESENT AND FUTURE OF HEMATOLOGY Chairs:  D. Hoelzer (Johann Wolfgang Goethe Institute, Frankfurt, Germany) R. Foà (University “La Sapienza”, Rome, Italy) MALIGNANCY: HOW DOES A NORMAL CELL TRANSFORM TO A LEUKEMIC CELL J.E. Dick (University Health Network, Princess Margareth Hospital, Toronto, Canada) HEMOSTASIS AND THROMBOSIS IN THE INDIVIDUAL K.G. Mann (University of Vermont, Burlington, USA) RED BLOOD CELLS: APLASTIC ANEMIA N. Young (National Heart, Lung and Blood Institute, Bethesda MD, USA) CLOSING CEREMONY & FAREWELL LUNCH BUFFET 14:00 - 15:00, Plenary room (A+B+C, Geneva Palexpo) Chairs:  E. Montserrat (Hospital Clinic Barcelona, Barcelona, Spain) A. Gratwohl (Kantonsspital Basel, Basel, Switzerland)